- Province, MA;
- Goetz, MP;
- Brauch, H;
- Flockhart, DA;
- Hebert, JM;
- Whaley, R;
- Suman, VJ;
- Schroth, W;
- Winter, S;
- Zembutsu, H;
- Mushiroda, T;
- Newman, WG;
- Lee, M‐T M;
- Ambrosone, CB;
- Beckmann, MW;
- Choi, J‐Y;
- Dieudonné, A‐S;
- Fasching, PA;
- Ferraldeschi, R;
- Gong, L;
- Haschke‐Becher, E;
- Howell, A;
- Jordan, LB;
- Hamann, U;
- Kiyotani, K;
- Krippl, P;
- Lambrechts, D;
- Latif, A;
- Langsenlehner, U;
- Lorizio, W;
- Neven, P;
- Nguyen, AT;
- Park, B‐W;
- Purdie, CA;
- Quinlan, P;
- Renner, W;
- Schmidt, M;
- Schwab, M;
- Shin, J‐G;
- Stingl, JC;
- Wegman, P;
- Wingren, S;
- Wu, AHB;
- Ziv, E;
- Zirpoli, G;
- Thompson, AM;
- Jordan, VC;
- Nakamura, Y;
- Altman, RB;
- Ames, MM;
- Weinshilboum, RM;
- Eichelbaum, M;
- Ingle, JN;
- Klein, TE;
- Consortium, International Tamoxifen Pharmacogenomics
The International Tamoxifen Pharmacogenomics Consortium was established to address the controversy regarding cytochrome P450 2D6 (CYP2D6) status and clinical outcomes in tamoxifen therapy. We performed a meta-analysis on data from 4,973 tamoxifen-treated patients (12 globally distributed sites). Using strict eligibility requirements (postmenopausal women with estrogen receptor-positive breast cancer, receiving 20 mg/day tamoxifen for 5 years, criterion 1); CYP2D6 poor metabolizer status was associated with poorer invasive disease-free survival (IDFS: hazard ratio = 1.25; 95% confidence interval = 1.06, 1.47; P = 0.009). However, CYP2D6 status was not statistically significant when tamoxifen duration, menopausal status, and annual follow-up were not specified (criterion 2, n = 2,443; P = 0.25) or when no exclusions were applied (criterion 3, n = 4,935; P = 0.38). Although CYP2D6 is a strong predictor of IDFS using strict inclusion criteria, because the results are not robust to inclusion criteria (these were not defined a priori), prospective studies are necessary to fully establish the value of CYP2D6 genotyping in tamoxifen therapy.